Fibrotech Announces Positive Phase Ia Results For Anti-Fibrotic FT011
3/10/2014 9:19:23 AM
MELBOURNE, Australia--(BUSINESS WIRE)--Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg. At the same time Fibrotech announced the commencement of a Phase Ib trial involving patients with diabetic nephropathy associated with Type 1 or Type 2 diabetes. Both trials have been and will be conducted in Australia.
Help employers find you! Check out all the jobs and post your resume.
comments powered by